MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
Top Page
MiNK Therapeutics
(NASDAQ:INKT)
Select Model
Select Model
Rating:58Neutral
Price Target:
$14.50
▲(2.62% Upside)
Action:ReiteratedDate:04/17/26
The score is held back primarily by weak financial performance (pre-revenue losses, negative cash flow, negative equity, and 2025 volatility). Offsetting this are constructive technical momentum and a generally positive earnings call driven by clinical progress, specific 2026 milestones, and improved cost discipline, though runway and execution risk remain key constraints.
Positive Factors
Durable oncology efficacy
Durable, long‑duration responses in checkpoint‑refractory solid tumors indicate a reproducible mechanism of action and potential for meaningful clinical differentiation. Persistent remissions support durable benefit claims and improve odds of later regulatory and commercial value when scaled beyond early cohorts.
Negative Factors
Pre‑revenue losses & weak balance sheet
Sustained pre‑revenue losses and negative equity are structural solvency concerns: accumulated deficits limit financial flexibility and increase dependence on external capital. This constrains strategic optionality and raises execution risk for multi‑site, randomized programs without reliable milestone or commercial revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Durable oncology efficacy
Durable, long‑duration responses in checkpoint‑refractory solid tumors indicate a reproducible mechanism of action and potential for meaningful clinical differentiation. Persistent remissions support durable benefit claims and improve odds of later regulatory and commercial value when scaled beyond early cohorts.
Read all positive factors
MiNK Therapeutics (INKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.26M
Dividend YieldN/A
Average Volume (3M)39.56K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue GrowthN/A
EPS Growth21.48%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.52
Shares Outstanding4,965,858
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-206.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit73.09K
Enterprise Value/Ebitda1.08K
Forecast
1Y Price Target
$35.00Price Target Upside147.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.5
Revenue Forecast (FY)N/A
MiNK Therapeutics Business Overview & Revenue Model
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-media...
How the Company Makes Money
MiNK Therapeutics does not have consistent commercial product sales and, as a clinical-stage company, its operations have primarily been funded through external financing rather than recurring operating revenue. The company may generate revenue fr...
MiNK Therapeutics Earnings Call Summary
Earnings Call Date:Mar 31, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed multiple substantive clinical and translational wins (durable oncology responses, strong ARDS signals, initiation of randomized pulmonary and GvHD programs), meaningful nondilutive funding and improved capital efficiency (cash up ~191%, operating costs down ~40%). However, the company remains early‑stage with ongoing net losses (FY loss up ~16%), a limited runway extended only through 2026, and some program timing and partnership uncertainties. On balance the strength of the clinical data, funding traction and disciplined cost reduction outweigh near‑term financial and operational risks.Positive Updates
Strong clinical activity and durability in oncology
MiNK reported durable clinical responses in heavily pretreated, checkpoint-refractory solid tumors: median overall survival exceeding 23 months in combination with PD-1 therapies, and complete remissions extending beyond 2 years across multiple tumor types (gastric, thymoma, renal, adenoid cystic, lung). These data support mechanism-of-action observations including activation/expansion of dendritic cells, macrophage repolarization, and reinvigoration of exhausted T cells with controlled cytokine increases (IFN-γ, IL-2, TNF-α) and favorable safety.
Negative Updates
Continuing net losses and increased full‑year loss
Net loss for FY2025 was $12.5 million compared with $10.8 million in FY2024, an increase of ~$1.7M (≈16% year‑over‑year). Q4 2025 net loss was $2.6M versus $2.5M in Q4 2024 (≈4% increase), although Q4 net loss per share improved to $0.56 from $0.62 (≈9.7% improvement).
Read all updates
Q4-2025 Updates
Positive
Negative
Strong clinical activity and durability in oncology
MiNK reported durable clinical responses in heavily pretreated, checkpoint-refractory solid tumors: median overall survival exceeding 23 months in combination with PD-1 therapies, and complete remissions extending beyond 2 years across multiple tumor types (gastric, thymoma, renal, adenoid cystic, lung). These data support mechanism-of-action observations including activation/expansion of dendritic cells, macrophage repolarization, and reinvigoration of exhausted T cells with controlled cytokine increases (IFN-γ, IL-2, TNF-α) and favorable safety.
Read all positive updates
Company Guidance
The company provided specific, metric-driven guidance: in H1 2026 MiNK expects to initiate its randomized Phase II (expandable to Phase II/III) ARDS/hypoxemic pneumonia study and activate/dose its GvHD trial, with initial clinical data from both programs anticipated in H2 2026; a second‑line gastric cancer Phase II readout will be presented in H1 2026 and MiNK-215 IND-enablement updates are expected in ~3–5 months. Key clinical metrics cited include an ARDS addressable population of ~200,000–300,000 patients/year with 30%–40% mortality, prior Phase I/II dosing of up to 1 billion cells in ventilated and/or VV‑ECMO patients with no cytokine release, reported 70% survival versus 10% hospital controls, and oncology signals showing median overall survival >23 months and complete remissions >2 years in heavily pretreated patients. Financially, year-end cash rose to ~$13.4M from $4.6M with operating costs down ~40% year-over-year, an additional $3M raised post-year-end via ATM, Q4 2025 net loss of $2.6M ($0.56/share) and FY 2025 net loss of $12.5M ($2.93/share), plus >$1M in C‑Further nondilutive support and “meaningful double‑digit” downstream commercial participation retained.MiNK Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -181.75K | -215.44K | -204.62K | -121.75K | -77.96K |
| EBITDA | -12.31M | -10.57M | -22.25M | -27.87M | -27.70M |
| Net Income | -12.49M | -10.78M | -22.46M | -27.99M | -30.21M |
Balance Sheet | |||||
| Total Assets | 14.24M | 5.72M | 4.55M | 21.47M | 40.24M |
| Cash, Cash Equivalents and Short-Term Investments | 13.36B | 4.58M | 3.37M | 19.64M | 38.89M |
| Total Debt | 5.18M | 4.92M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 28.47M | 25.31M | 22.61M | 21.87M | 16.47M |
| Stockholders Equity | -14.23M | -19.59M | -18.06M | -401.30K | 23.78M |
Cash Flow | |||||
| Free Cash Flow | -5.93B | -9.56M | -15.84M | -19.12M | -13.08M |
| Operating Cash Flow | -5.93B | -9.56M | -15.76M | -18.87M | -12.83M |
| Investing Cash Flow | 0.00 | 0.00 | -73.56K | -250.05K | -248.98K |
| Financing Cash Flow | 14.72B | 10.82M | -407.17K | -155.60K | 49.26M |
MiNK Therapeutics Technical Analysis
Positive
14.13
Price Trends
10.88
Positive
11.36
Positive
13.31
Positive
Market Momentum
0.67
Negative
68.14
Neutral
85.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INKT, the sentiment is Positive. The current price of 14.13 is above the 20-day moving average (MA) of 10.87, above the 50-day MA of 10.88, and above the 200-day MA of 13.31, indicating a bullish trend. The MACD of 0.67 indicates Negative momentum. The RSI at 68.14 is Neutral, neither overbought nor oversold. The STOCH value of 85.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INKT.
MiNK Therapeutics Risk Analysis
MiNK Therapeutics disclosed 76 risk factors in its most recent earnings report. MiNK Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MiNK Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $154.50M | 1.57 | 43.14% | ― | ― | 814.20% | |
58 Neutral | $64.26M | -3.81 | ― | ― | ― | 21.48% | |
55 Neutral | $441.79M | -1.31 | 158.91% | ― | -7.55% | -13.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $39.00M | -2.04 | -83.24% | ― | -100.00% | 55.10% | |
40 Underperform | $20.05M | -2.00 | 7743.57% | ― | ― | 2.26% |
* Healthcare Sector Average
INKT
MiNK Therapeutics
14.21
6.95
95.73%
VERU
Veru
2.44
-2.79
-53.35%
ORMP
Oramed Pharm
3.88
1.88
93.61%
ARMP
Armata Pharmaceuticals
11.50
10.26
827.42%
QNCX
Quince Therapeutics
1.37
-8.54
-86.17%
MiNK Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
Positive
Mar 27, 2026
In response to recent investor inquiries, MiNK Therapeutics clarified that it is in active discussions with multiple parties about potential clinical combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy. The company...
Business Operations and StrategyExecutive/Board Changes
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
Neutral
Mar 19, 2026
On March 13, 2026, MiNK Therapeutics appointed Melissa Orilall, currently Vice President of Global Financial Operations at Agenus Inc., as its Principal Financial Officer, formalizing her oversight of general accounting, close procedures, and fina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.